Screener
10x Genomics, Inc. TXG Products and services revenue — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by 10x Genomics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: 10x Genomics, Inc.’s 10-Q, filed August 7, 2026.
- Filed
- Aug 6, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-054491
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Products and services revenue | $149,094 | $145,157 | $298,990 | $282,980 |
| License and royalty revenue | 1,942 | 27,751 | 2,889 | 44,811 |
| Revenue | 151,036 | 172,908 | 301,879 | 327,791 |
| Cost of products and services revenue | 38,539 | 47,824 | 83,204 | 97,262 |
| Gross profit | 112,497 | 125,084 | 218,675 | 230,529 |
| Operating expenses: | ||||
| Research and development | 56,791 | 61,224 | 113,638 | 125,469 |
| Selling, general and administrative | 78,661 | 74,434 | 145,038 | 164,162 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is 10x Genomics, Inc.'s products and services revenue — revenue?
- 10x Genomics, Inc. (TXG) reported products and services revenue — revenue of $149.09M in Q2 2026.
- How has 10x Genomics, Inc.'s products and services revenue — revenue changed year-over-year?
- 10x Genomics, Inc.'s products and services revenue — revenue increased by 2.7% year-over-year, from $145.16M to $149.09M.
- What is the long-term trend for 10x Genomics, Inc.'s products and services revenue — revenue?
- Over 2 years (2023 to 2025), 10x Genomics, Inc.'s products and services revenue — revenue has grown at a -1.8% compound annual growth rate (CAGR), from $618.73M to $596.69M.
- What does products and services revenue — revenue mean?
- This metric represents the total revenue generated from the sale of core life science instruments, consumables, and associated software solutions. It serves as a primary indicator of market adoption for the company's proprietary technology platforms and the recurring demand for its specialized biological analysis tools. Monitoring this figure helps investors assess the company's ability to monetize its installed base and sustain long-term growth within the life sciences sector.
Ask your AI about 10x Genomics, Inc.'s products and services revenue — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude